Research & Development
Intellectual Property Protection for Tetra Discovery Partners' BPN14770 Boosted with Issuance of New US Patent
11 October 2018 - - The US Patent and Trademark Office has issued a third patent covering US-based biotechnology company Tetra Discovery Partners' selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds, the company said.

The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson's disease, stroke and ischemia.

This new patent further builds on the intellectual property protections for the company's lead compound, adding to previously issued patents covering BPN 14770's composition and use in the treatment of Alzheimer's disease," said Mark Gurney, Ph.D., chairman and chief executive officer of Tetra.

BPN14770 is a novel therapeutic agent that selectively inhibits phosphodiesterase-4D (PDE4D) to enhance early and late stages of memory formation.

This unique mechanism of action has the potential to improve cognitive and memory function in devastating disorders including Fragile X Syndrome, Alzheimer's disease and other dementias, learning/developmental disabilities and schizophrenia.

Tetra Discovery has initiated an investigational Phase 2 study of BPN14770 in adults with Fragile X Syndrome, an indication for which BPN14770 has received Orphan Drug Designation from the US Food and Drug Administration.

Preparations are also under way to initiate a Phase 2 trial of BPN14770 in patients with Alzheimer's disease. BPN14770 is currently approved for investigational use only by the US Food and Drug Administration and is not currently approved for marketing in any territory.

Tetra Discovery Partners is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from neuro-developmental conditions such as Fragile X Syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders.

Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4, an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury.

Tetra Discovery Partners is headquartered in Grand Rapids, Michigan.
Login
Username:

Password:


Related Headlines